Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

Abstract Number: 931 • 2019 ACR/ARP Annual Meeting
Ultra-Low Doses of Rituximab for Retreatment of RA: A Randomized Controlled Non-Inferiority Trial
Lise Verhoef¹, Nathan den Broeder ¹, Rogier Thurlings ², Willemijn van der Laan ¹, Wilfred van der Weele ³, Marc Kok ⁴, Hein Bernelot Moens ⁵, Thasia Woodworth ⁶, Bart van den Bemt ¹, Frank van den Hoogen ¹ and Alfons den Broeder ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Reade, Amsterdam, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵Ziekenhuisgroep Twente, Almelo, Netherlands, ⁶University of California, Los Angeles, CA
Background/Purpose: Rituximab is an effective treatment for patients with RA. 1000mg (1×1000mg or 2×500mg) has similar six-month efficacy as the registered dose of 2×1000mg.(1) Based…
Abstract Number: 147 • 2018 ACR/ARHP Annual Meeting
T Follicular Helper Cell Phenotype in RA Patients Receiving Rituximab
Betty Hsiao¹, Jin-Young Choi² and Joseph E. Craft³, ¹Yale University School of Medicine, New Haven, CT, ²Section of Rheumatology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, ³Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT
Background/Purpose: B and T cells contribute to tissue injury in rheumatoid arthritis (RA). Rituximab (RTX), an anti-CD20 monoclonal antibody, is used for the treatment of…
Abstract Number: 521 • 2018 ACR/ARHP Annual Meeting
The Lung in an English Cohort of Rheumatoid Arthritis Patients – an Overview of Different Types of Involvement and Treatment
Ana Catarina Duarte¹, Maria José Leandro² and Joanna Porter³, ¹Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ²Center for Rheumatology, University College London, London, United Kingdom, London, United Kingdom, ³Department of Respiratory Medicine, University College London, London, United Kingdom, London, United Kingdom
Background/Purpose: Lung disease is described in 5–20% of pts (pts) with RA and affects parenchyma, pleura, airways and vasculature; drug-induced pulmonary disease also occurs. It…
Abstract Number: 617 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience
Candice Low¹, Richard Conway¹, Francis Young², Eamonn S. Molloy³, Anne Barbara Mongey³, Oliver FitzGerald⁴, Anthony G. Wilson⁵, Ursula Fearon⁶ and Douglas J. Veale¹, ¹Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ³Saint Vincent's University Hospital, Dublin 4, Ireland, ⁴Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁵UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, ⁶Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Rituximab is an effective treatment for rheumatoid arthritis (RA). Data on long-term outcomes following rituximab treatment are limited. The aim of this study was…
Abstract Number: 1500 • 2018 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Gill Wheater², Mohsen Elshahaly³, Janneke Tekstra¹, Y.K. Onno Teng⁴, Floris PJG Lafeber¹, Ching Chang Hwang⁵, Xinyu Liu⁶, Eric H. Sasso⁵ and Jacob van Laar¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Department of Biochemistry, The James Cook University Hospital, Middlesbrough, UK, Middlesbrough, United Kingdom, ³Department of Rheumatology & Rehabilitation, Suez Canal University, Ismailia, Egypt, Ismailia, Egypt, ⁴Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁵Crescendo Bioscience, San Francisco, CA, USA, South San Francisco, CA, ⁶Crescendo Bioscience, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score was developed to objectively measure disease activity for patients with rheumatoid arthritis (RA).1 The MBDA score is calculated…
Abstract Number: 2515 • 2018 ACR/ARHP Annual Meeting
Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study
Chang-Hee Suh¹, Dae-Hyun Yoo², Won Park³, Seung-Cheol Shim⁴, Sang-Joon Lee⁵, Yun Ju Bae⁵, Sang Eun Han⁵ and Sang Mi Lee⁵, ¹Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁵CELLTRION, Inc., Incheon, Korea, Republic of (South)
Background/Purpose: CT-P10 is a biosimilar of the reference rituximab (RTX) and has been approved by several regulatory agencies including EMA. Pharmacokinetic and therapeutic equivalence from…
Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Ana Martínez^1,2, Chamaida Plasencia^2,3, Victoria Navarro-Compán², Borja Hernández-Breijo², Dora Pascual-Salcedo², Pilar Nozal⁴, Cristina Diego⁴, Irene Monjo^2,3, Laura Nuño^3,5 and Alejandro Balsa^2,6, ¹Immunology. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴La Paz University Hospital, Immunology, Madrid, Spain, ⁵Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
Abstract Number: 2385 • 2017 ACR/ARHP Annual Meeting
High Incidence of Hepatitis Related to HBV Reactivation in Rheumatoid Arthritis Patients with Resolved Hepatitis B Infection during Rituximab Treatment
Ming-Han Chen¹, Yen-Po Tsao², Yi-Hsiang Huang³, Chung-Tei Chou⁴ and Chang Youh Tsai², ¹Division of Allergy- Immunology- Rheumatology, Department of Medicine, Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ²Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ³Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
AbstractBackground/Purpose: Rituximab-based chemotherapy can induce hepatitis B virus (HBV) reactivation (HBVr) in patients with hematological malignancies who have been exposed to HBV infection. However, informative…
Abstract Number: 2402 • 2017 ACR/ARHP Annual Meeting
Rituximab in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 32 Patients
Carlos Fernández-Díaz¹, Delia Reina², Paula Rubio-Muñoz³, Ana Urruticoechea-Arana⁴, María Carrasco-cubero⁵, María Martín-López⁶, Jose A. Miranda-Filloy⁷, Ignacio Villa-Blanco⁸, Ana Milena Millan⁹, Ivan Castellví¹⁰, Olga Maiz-Alonso¹¹, Antonio Juan¹², Fátima Álvarez Reyes¹³, José Luis Martín-Varillas¹, Nuria Vegas-Revenga¹, Ricardo Blanco¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ³Rheumatology,, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital Infanta Cristina, Badajoz, Spain, ⁶Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Rheumatology Division, Hospital Lucus Augusti, Lugo, Spain, ⁸Hospital de Sierrallana, Sierrallana, Spain, ⁹Unitat de Reumatologia. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, ¹²Hospital Universitario Son Llàtzer. Rheumatology, Palma de Mallorca, Spain, ¹³Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain
Background/Purpose: Anti-TNFα drugs and several conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) have been involved in the development of Interstitial Lung Disease (ILD).…
Abstract Number: 2445 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab Biosimilar, CT-P10, after a Single Switch from Innovator Rituximabs in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 72 Weeks
Seung-Cheol Shim¹, Ljubinka Bozic Majstorovic², Alfredo Berrocal Kasay³, Elias Chalouhi El-Khouri⁴, Fedra Irazoque-Palazuelos⁵, Francisco Cons Molina⁶, Francisco G. Medina-Rodriguez⁷, Pedro Miranda⁸, Pavel Shesternya⁹, Jose Chavez Corrales¹⁰, Piotr Wiland¹¹, Slawomir Jeka¹², Olena Garmish¹³, Pawel Hrycaj¹⁴, Natalia Fomina¹⁵, Won Park¹⁶, Chang-Hee Suh¹⁷, Sang-Joon Lee¹⁸, Sung Young Lee¹⁹ and Dae-Hyun Yoo²⁰, ¹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ²Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, ³ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, ⁴Clinica Internacional, Lima, Peru, ⁵Centro de Invstigacion y Tratamiento Reumatologico S.C, Mexico City, Mexico, ⁶Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁷Rheumatology, LaSalle University, Mexico City, Mexico, ⁸Centro De Estudios Reumatológicos, Santiago, Chile, ⁹Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹⁰Clinica San Borja, Lima, Peru, ¹¹Department and Clinic of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ¹²2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ¹³Institute of Cardiology named by M.D. Strazhesko NAMS of Ukraine, Kyiv, Ukraine, ¹⁴Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ¹⁵Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation, ¹⁶Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ¹⁷Ajou University School of Medicine, Suwon, Korea, Republic of (South), ¹⁸CELLTRION, Inc., Incheon, Korea, Republic of (South), ¹⁹Clinical Planning Department, CELLTRION, Inc., Incheon, Korea, Republic of (South), ²⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Similarity of pharmacokinetic, efficacy and safety between CT-P10 and reference rituximab (RTX) were shown in the phase 3 randomized controlled trial (NCT02149121) up to…
Abstract Number: 2461 • 2017 ACR/ARHP Annual Meeting
Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Sang-Joon Lee⁵, Yun Ju Bae⁵, Chan Park⁵ and Noo Ri Han⁵, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁵CELLTRION, Inc., Incheon, Korea, Republic of (South)
Background/Purpose: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in RA patients.1 However, there are limited…
Abstract Number: 2486 • 2017 ACR/ARHP Annual Meeting
Rituximab Is an Attractive Proposition to Treat Difficult Active RA in Indian (Asia) Patients: Initial Results of a Non Commercial Initiative Using an Initial Regimen of Two 500 Mg Infusions (fortnightly) and a Third 500 Mg Infusion at 6 Weeks in Case of Inadequate Response(ACR 50)
Arvind Chopra¹, KIRAN ADAM², NACHIKET KULKARNI³, Anuradha Venugopalan⁴, Toktam Kainifard⁵ and Manjit Saluja⁶, ¹Center for Rheumatic Diseases, Pune, India, Pune, India, ²Rheumatology physician, PUNE, India, ³MD, DNB, PUNE, India, ⁴Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India, ⁵Rheumatology, Consultant research and Dietitian, Pune, India, ⁶Rheumatology, Co-ordinator Research, Pune, India
Background/Purpose: Considering the huge burden of RA in India, the use of biologic DMARDs is miniscule. The major deterrents are cost, poor awareness and few…
Abstract Number: 39 • 2017 ACR/ARHP Annual Meeting
Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment
Zoltán Konthur¹, Melvin Michael Wiemkes², Thomas Häupl², Gerd R. Burmester² and Karl Skriner², ¹Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann-Rheum-Dis. 2005 Feb;64(2):246-52)…
Abstract Number: 496 • 2017 ACR/ARHP Annual Meeting
Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated with Increased Rates of Serious Infections
Dimitrios A. Pappas^1,2, George W. Reed^1,3, Steve Zlotnick⁴, Jennie Best⁴, Robert Magner³, Gioia Persuitte¹ and Jeffrey D Greenberg^1,5, ¹Corrona, LLC, Southborough, MA, ²Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ³University of Massachusetts Medical School, Worcester, MA, ⁴Genentech, Inc., South San Francisco, CA, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Extended observations in clinical trials have not demonstrated an increased risk of serious infection events (SIE) in patients with rheumatoid arthritis (RA) treated with…
Abstract Number: 1346 • 2017 ACR/ARHP Annual Meeting
Selective Effect of Rituximab on IgG4 Anti-CCP Autoantibodies in Rheumatoid Arthritis Patients
Mercedes Rincon^1,2, Sarah Kelso³, Janice Bunn⁴ and Sheldon Cooper⁵, ¹Department of Medicine/Rheumatology, University of Vermont, Burlingont VT, VT, ²Department of Medicine/Immunobiology, University of Vermont, Burlington, VT, ³Department of Medicine/Rheumatology, Univeristy of Vermont, Burlington, VT, ⁴Mathematics and Statistics, University of Vermont, Burlington, VT, ⁵Department of Medicine/Rheumatology, University of Vermont, Burlington, VT
Background/Purpose: Autoantibodies have long been recognized to be present in patients with RA, but it is more recent that autoantibodies against citrullinated proteins (anti-CCP) are…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].